Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 16/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 16/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 14/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 14/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 12/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233307 | 0.96 | — | — | |
| SCHEMBL14673280 | 0.92 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL14523284 | 0.87 | — | — | |
| SCHEMBL56397 | 0.87 | — | — | |
| SCHEMBL7249921 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL20534633 | 0.83 | — | — | |
| SCHEMBL14249896 | 0.82 | CCR5 (0.50) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL27316 | 0.80 | — | — | |
| SCHEMBL15193376 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL2186118 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2003-11-13 | — | — | US | disclosed |
| EP-1301510-A1 | NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | AstraZeneca AB (SE) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002004446-A1 | NEW BISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212095-A1 | New bispidine compounds and their use in the treatment of cardiac arrhythmias | KCNH1, LBR, CACNA1E | CHRNB2 460/4885CHRNA4 414/4885CHRNB4 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.